Latest news with #IPAustralia
Sydney Morning Herald
2 days ago
- Business
- Sydney Morning Herald
Olympic organisers win 2032 trademark battle with local council
Brisbane's Olympic Games organising committee faced an unexpected challenge in their bid to protect Games branding when a local council beat them to the trademark for 'Logan 2032' by just 13 days, before ultimately pulling out of the race. The Brisbane 2032 Organising Committee and Logan City Council both applied to IP Australia to claim variations of 'Logan 2032' as a trademark earlier this year. Logan 2032 is one of 14 location-based trademarks the organising committee is trying to protect, along with others such as Cairns 2032, Toowoomba 2032 and Rockhampton 2032 – all locations where Olympic and Paralympic competition is to be held. Brisbane 2032 was granted protection in January 2023. The council, meanwhile, sought to trademark a nondescript 'LOGAN2032' logo, in the same font as its main corporate branding. The council's application was made on April 29, with the organising committee's application 13 days later on May 12 – an application IP Australia examiner Lucy Raftery cited in her initial rejection of the organising committee's request. 'I have considered the differences between the trade marks, this being the lack of space between Logan and 2032 in the earlier trade mark. These differences, however, in the context of the goods and services claimed, are not sufficient to prevent confusion in the marketplace,' Raftery wrote in IP Australia's June 17 letter to Allens Patent & Trade Mark Attorneys, who were representing Brisbane 2032. 'As such, consumers are likely to assume that the goods and services provided under your trade mark and the earlier trade marks come from the same, or related, trade source.' Losing that administrative race had the potential to derail the organising committee's plans, but a Logan City Council spokeswoman confirmed the municipality would withdraw its bid. 'Council initially lodged an application earlier this year to safeguard the term for potential future promotional use, and to help position the city's interests in the lead-up to the Brisbane 2032 Olympic and Paralympic Games,' she said.
The Age
2 days ago
- Business
- The Age
Olympic organisers win 2032 trademark battle with local council
Brisbane's Olympic Games organising committee faced an unexpected challenge in their bid to protect Games branding when a local council beat them to the trademark for 'Logan 2032' by just 13 days, before ultimately pulling out of the race. The Brisbane 2032 Organising Committee and Logan City Council both applied to IP Australia to claim variations of 'Logan 2032' as a trademark earlier this year. Logan 2032 is one of 14 location-based trademarks the organising committee is trying to protect, along with others such as Cairns 2032, Toowoomba 2032 and Rockhampton 2032 – all locations where Olympic and Paralympic competition is to be held. Brisbane 2032 was granted protection in January 2023. The council, meanwhile, sought to trademark a nondescript 'LOGAN2032' logo, in the same font as its main corporate branding. The council's application was made on April 29, with the organising committee's application 13 days later on May 12 – an application IP Australia examiner Lucy Raftery cited in her initial rejection of the organising committee's request. 'I have considered the differences between the trade marks, this being the lack of space between Logan and 2032 in the earlier trade mark. These differences, however, in the context of the goods and services claimed, are not sufficient to prevent confusion in the marketplace,' Raftery wrote in IP Australia's June 17 letter to Allens Patent & Trade Mark Attorneys, who were representing Brisbane 2032. 'As such, consumers are likely to assume that the goods and services provided under your trade mark and the earlier trade marks come from the same, or related, trade source.' Losing that administrative race had the potential to derail the organising committee's plans, but a Logan City Council spokeswoman confirmed the municipality would withdraw its bid. 'Council initially lodged an application earlier this year to safeguard the term for potential future promotional use, and to help position the city's interests in the lead-up to the Brisbane 2032 Olympic and Paralympic Games,' she said.
Associated Press
30-06-2025
- Business
- Associated Press
Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic
TARPON SPRINGS, Fla., June 30, 2025 -- Allarity Therapeutics, Inc. ('Allarity' or the 'Company') (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as a personalized cancer treatment using its proprietary, drug-specific Drug Response Predictor (DRP®) patient selection technology—today announced that IP Australia, the Australian Government agency that administers intellectual property rights in the country, has formally accepted the Company's patent application for its DRP® companion diagnostic specific to stenoparib. The acceptance covers 40 claims and marks a key step in Allarity's global strategy to protect the potential international commercialization of its proprietary DRP® platform alongside the clinical development of stenoparib. The granted patent will be officially advertised in the Australian Official Journal of Patents on June 26, 2025, followed by a three-month opposition period. If unopposed, the patent is expected to be granted within 20 working days thereafter. Thomas Jensen, CEO of Allarity Therapeutics, commented: 'This latest patent acceptance from Australia represents another important achievement in our efforts to secure international IP protection for our DRP® technology. As we continue advancing stenoparib through Phase 2 trials toward U.S. regulatory approval, we are also building a robust intellectual property position in key global markets.' Allarity previously secured a European patent for the Stenoparib DRP® and holds 18 granted patents for drug-specific DRPs, including eight in the United States. Patent applications for the Stenoparib DRP® remain pending in the U.S., Canada, Japan, China, and India. About Stenoparib Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the WNT signaling pathway. Aberrant WNT/β-catenin signaling has been implicated in the development and progression of numerous cancers. By inhibiting PARP and blocking WNT pathway activation, stenoparib's unique therapeutic action shows potential as a promising therapeutic for many cancer types, including ovarian cancer. Allarity has secured exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and 2X-121. About the Drug Response Predictor – DRP® Companion Diagnostic Allarity uses its drug-specific DRP® to select those patients who, by the gene expression signature of their cancer, may have a high likelihood of benefiting from a specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high, drug-specific DRP score, the therapeutic benefit rate may be enhanced. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes. DRP is based on messenger RNA expression profiles from patient biopsies. The DRP® platform has shown an ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients across dozens of clinical studies (both retrospective and prospective). The DRP platform, which may be useful in all cancer types and is patented for dozens of anti-cancer drugs, has been extensively published in the peer-reviewed literature. About Allarity Therapeutics Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The Company is focused on development of stenoparib, a novel PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP® technology to develop a companion diagnostic that can be used to select those patients expected to derive the greatest clinical benefit from stenoparib. Allarity is headquartered in the U.S., with a research facility in Denmark, and is committed to addressing significant unmet medical needs in cancer treatment. For more information, visit Follow Allarity on Social Media LinkedIn: Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company's current expectations or forecasts of future events. The words 'anticipates,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intends,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predicts,' 'project,' 'should,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, statements regarding the expected grant and scope of the Australian patent for the Stenoparib DRP®; the anticipated contribution of this patent to the Company's global intellectual property strategy; and the Company's ability to advance and commercialize stenoparib in Australia and other key markets. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the potential for opposition to the patent grant; changes in regulatory timelines or requirements; failure to obtain regulatory approval for stenoparib or its companion diagnostic; and risks inherent in developing and commercializing biopharmaceutical products. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled 'Risk Factors' in our Form 10-K annual report filed with the Securities and Exchange Commission (the 'SEC') on March 31, 2025, available at the SEC's website at and as well as discussions of potential risks, uncertainties and other important factors in the Company's subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law. ### Company Contact: [email protected] Media Contact: Thomas Pedersen Carrotize PR & Communications +45 6062 9390 [email protected] Attachment
News.com.au
11-06-2025
- Business
- News.com.au
Brisbane Broncos submit bold new logo for trademark
The Brisbane Broncos appear to be considering a rebrand for the first time in nearly 25 years. A newly designed, simplistic horse head logo has been quietly submitted to IP Australia for trademark protection. While the trademark image is black and white, it's expected any final version would draw on the club's traditional maroon, white, and gold colour scheme. FOX LEAGUE, available on Kayo Sports, is the only place to watch every game of every round in the 2025 NRL Telstra Premiership, LIVE with no ad-breaks during play. New to Kayo? Get your first month for just $1. Limited-time offer. A club spokesperson confirmed the filing but stopped short of revealing whether the logo would appear on next season's jerseys. 'A newly created corporate design was recently submitted to IP Australia,' she said. 'The design has not been approved, accepted or registered at this point.' The new design follows a global trend of cutting back on detail to favour bold colours and a clean silhouette. In the 20th century, NRL logos were generally bold and cartoonish, but it appears the corporate machines behind Australia's biggest clubs are pushing for a new sense of relevancy. Logo changes in the NRL aren't new. Clubs like the Canterbury Bulldogs and Wests Tigers have reworked their visual identity in recent decades, often seeking to modernise their image while maintaining ties to tradition. Associate Professor Sheranne Fairley from the University of Queensland said the Broncos' relatively modern history makes it more flexible than older clubs like Carlton. Founded in 1988, the Broncos aren't as constrained by tradition, though changes still carry weight with fans,' she told Nine Newspapers. She speculated the stripe in the new logo might represent the Brisbane River, a nod to the city's identity as 'the river city.' The current Broncos logo was first adopted in 2000 and later refined in 2006. It replaced the club's original 1988 crest, which also featured a stylised horse's head. The Broncos have not been afraid to mix things up in recent years and the team's radical shift to a black jersey for their win over the Gold Coast Titans. he black jerseys along with black shorts and black socks are being worn to make a powerful statement for the club's dedicated Mental Health Round. The jersey was designed in collaboration with Broncos Charity Partner, Black Dog Institute, with the club to make a major donation from the proceeds of the jersey to the organisation.
1News
08-05-2025
- Business
- 1News
Lord of the Rings says Australian burger chain name shall not pass
In a battle between a fantasy book franchise and an Australian vegan fast-food chain, who will be named "Lord of the" courtroom? The rights holder of the Lord of the Rings novels and films, Middle-earth Enterprises, has launched another attack to take its precious title. It follows an unsuccessful bid in March, where the franchise attempted to block an Australian vegan hamburger chain from trademarking the words "Lord of the" in its name. Lord of the Fries has been selling items under its name since 2004 and sought to offer plant-based macaroni and cheese under the trademark in 2022. The franchise was in New Zealand from 2016 until last June when its franchisor, Chip Lord NZ, went into liquidation. The case came before a registrar of trademarks in the federal government agency, IP Australia. Middle-earth argued it had been successful in other similar trademark applications made globally, and used the mark to sell various items including boardgames, clothing and toys. But Lord of the Fries said there were many examples of similar marks including Lord of the Pies and the business operated as a niche in an entirely different reputation to the Middle-earth franchise. The registrar delegate, Nicholas Smith, found the names were not deceptively similar and that Middle-earth had cherry-picked evidence in suggesting the connection. The matter has since been escalated to Sydney's Federal Court, after Middle-earth's lawyers filed an appeal against the IP Australia decision on March 25. The grounds for appeal were many and varied, the franchise's lawyer Shauna Ross told Justice Michael Lee. "My client's case is that Your Honour find the mark should be refused," she said today. The grounds for appeal included that Lord of the Fries does not own the trademark and that the IP Australia decision was adverse to Middle-earth, who is the true owner of the mark, Ross said. Justice Lee ordered both parties attend a mediation before June 20. If the case is not resolved through mediation, Justice Lee said he would assign the matter to a referee, who would then prepare a report for the decision. "The reality is, I don't have time to look at this matter this year," he said. Lord of the Fries and Middle-earth Enterprises have been contacted for comment.
